Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Retina Institute of Hawaii
• Treatments: Ranibizumab

Criteria

Inclusion Criteria:

• Ability to provide written informed consent and comply with study assessments for the full duration of the study

• Age greater then and equal 50 years

• Patients with active neovascular AMD

• Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months

• If the patient has bilateral disease and qualifies for the study, both eyes may be included

Exclusion Criteria:

• Subjects who meet any of the following criteria will be excluded from this study:

• Pregnancy or lactation

• Premenopausal women not using adequate contraception.

• Participation in another simultaneous medical investigation